Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIBRONEER-ACT of nerandomilast in fibrosing interstitial lung disease at risk of progression
CTR20263681Phase 3Active
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Fexinidazole in pulmonary fibrosis (PF), sponsored by Boehringer Ingelheim. Started Sep 2026; status: active.
02
Drugs
Fexinidazole
03
Conditions
pulmonary fibrosis (PF)
Beyond the preview
Go deeper on CTR20263681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263681.